Search

Difelikefalin

[L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665] … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.

Glycopyrronium

[L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. … Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers.[L33110] They are both quaternary ammonium compounds and long acting muscarinic antagonists.

Phenothrin

Zuclopenthixol

It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … This compound belongs to the thioxanthenes.

Etoperidone

[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]

Cemiplimab

[L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872] … By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.

Flurbiprofen

Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. … Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis.

Moxisylyte

[T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

Tetracycline

The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. … It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site.